Basilea appoints Ronald Scott as CEO

Also expands management team with addition of Heidi McDaid

Basilea Pharmaceutica of Basel, Switzerland has promoted Ronald Scott, previously chief operating officer, to chief executive. He takes up the role on 1 January 2013, succeeding Anthony Man, who has decided for personal reasons to leave the company.

For the last year Scott has been responsible for all of Basilea's operations including technical operations, commercial activities and finance. Prior to this position he was Basilea's CFO. Previously he held senior management positions in the pharmaceutical industry with more than 20 years of experience and in the financial sector.

In addition, Basilea has expanded its management committee to include Heidi McDaid, head of Global Human Resources. She joins the committee on 1 January.

The other members of the team remain Achim Kaufhold, chief medical officer since 2010; Ingrid Heinze-Krauss, chief technical officer since 2006; Laurenz Kellenberger, chief scientific officer since 2009; and Joachim Blatter, chief financial officer since 2012.

You may also like

Regulatory

Antifungal agent – isavuconazole

A new antifungal agent has been granted fast-track status by the FDA, as well as being designated a qualified infectious disease product, and an orphan drug for invasive aspergillosis and mucormycosis
Regulatory

IMI launches €223.7m project to combat antibiotic resistance

Academics and five pharma firms will share research data and improve efficiency of clinical trials
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now